Privia Health Group, Inc. (NASDAQ:PRVA) Receives Average Recommendation of "Buy" from Analysts

Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) has received an average rating of "Buy" from the sixteen research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $26.47.

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Privia Health Group from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Friday, November 29th. JMP Securities reissued a "market outperform" rating and set a $26.00 price objective on shares of Privia Health Group in a report on Friday, February 14th. Canaccord Genuity Group raised their target price on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Friday. Truist Financial boosted their target price on shares of Privia Health Group from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Finally, Needham & Company LLC increased their price target on Privia Health Group from $25.00 to $30.00 and gave the company a "buy" rating in a report on Friday.

Privia Health Group Price Performance

NASDAQ PRVA traded down $0.49 during mid-day trading on Thursday, reaching $24.97. The stock had a trading volume of 1,880,484 shares, compared to its average volume of 681,692. The stock has a market cap of $3.00 billion, a PE ratio of 249.72, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87. Privia Health Group has a 1 year low of $15.92 and a 1 year high of $26.04. The company has a fifty day moving average price of $22.40 and a 200 day moving average price of $20.60.

Remove Ads

Hedge Funds Weigh In On Privia Health Group

A number of large investors have recently bought and sold shares of PRVA. Mackenzie Financial Corp grew its position in shares of Privia Health Group by 87.2% in the fourth quarter. Mackenzie Financial Corp now owns 72,391 shares of the company's stock valued at $1,415,000 after purchasing an additional 33,728 shares during the period. Neo Ivy Capital Management lifted its stake in Privia Health Group by 81.5% in the 4th quarter. Neo Ivy Capital Management now owns 6,540 shares of the company's stock valued at $127,000 after buying an additional 2,936 shares in the last quarter. PharVision Advisers LLC acquired a new stake in Privia Health Group in the 4th quarter worth about $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Privia Health Group by 13.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 939,170 shares of the company's stock worth $18,361,000 after buying an additional 114,647 shares in the last quarter. Finally, Two Sigma Advisers LP purchased a new stake in Privia Health Group during the 4th quarter worth approximately $940,000. Institutional investors and hedge funds own 94.48% of the company's stock.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.